EUVIMEDEUVIMED entdecken
Crossref

PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer

Hongyan Zhang, Longlong Zhang, Yuna He, Dewei Jiang, Jian Sun, Qianmei Luo, Huichun Liang, Tiantian Wang, Fubing Li, Yu Tang, Zimo Yang, Wenjing Liu und 2 weitere

Cancer Letters · 2024-08 · 598 · 217112

DOI: 10.1016/j.canlet.2024.217112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024-08. Verfasst von Hongyan Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, China; Medical School, Kunming University of S…. Hauptthemen laut MEDLINE: Lapatinib, Breast Neoplasms, Drug Resistance, Neoplasm, Class I Phosphatidylinositol 3-Kinases. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: National Key Laboratory Foundation of China, National Natural Science Foundation of China, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although anti-HER2 therapy has made significant strides in reducing metastasis and relapse in HER2-positive breast cancer, resistance to agents like trastuzumab, pertuzumab, and lapatinib frequently develops in patients undergoing treatment. Previous studies suggest that the hyperactivation of the PI3K-AKT signaling pathway by PIK3CA/PTEN gene mutations is implicated in HER2 resistance. In this study, we introduce a novel PI3K-p110α Proteolysis TAargeting Chimera (PROTAC) that effectively inhibits the proliferation of breast cancer cells by degrading PI3K-p110α. When tested in two lapatinib-resistant cell lines, JIMT1 and MDA-MB-453, both of which harbor PIK3CA mutations, the PI3K PROTAC notably reduced cell proliferation and induced G1 phase cell cycle arrest. Importantly, even at very low concentrations, PI3K PROTAC restored sensitivity to lapatinib. Furthermore, the efficacy of PI3K PROTAC surpassed that of Alpelisib, a selective PI3K-p110α kinase inhibitor in clinic. The superior performance of PI3K PROTAC was also confirmed in lapatinib-resistant breast cancer xenograft tumors and patient-derived breast cancer organoids (PDOs). In conclusion, this study reveals that the novel PI3K PROTAC we synthesized could serve as an effective agent to overcome lapatinib resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LapatinibBreast NeoplasmsDrug Resistance, NeoplasmClass I Phosphatidylinositol 3-KinasesErb-b2 Receptor Tyrosine KinasesCell ProliferationXenograft Model Antitumor AssaysProteolysisHumansFemaleAnimalsCell Line, TumorMiceMutationAntineoplastic AgentsProtein Kinase InhibitorsMice, NudeThiazoles

Stichwörter der Autor:innen

AKTAlpelisibHER2 resistanceLapatinibPI3KPIK3CA mutationPROTAC

Substanzen

LapatinibClass I Phosphatidylinositol 3-KinasesErb-b2 Receptor Tyrosine KinasesAntineoplastic AgentsProtein Kinase InhibitorsThiazolesPIK3CA protein, humanERBB2 protein, humanAlpelisib

Autor:innen und Institutionen

  • Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, China; Medical School, Kunming University of Science and Technology, Kunming, 650500, China.
  • Academy of Biomedical Engineering, Kunming Medical University, Kunming, 650500, China.
  • State Key Laboratory of Molecular Oncology, MOE Key Laboratory of Protein Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, School of Pharmaceutical Sciences, Tsinghua University, Beiji…
  • Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, China.
  • The Third Affiliated Hospital, Kunming Medical University, Kunming, 650118, China.
  • Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, China; School of Life Science, University of Science & Technology of China, Hefei, 230027, Anhui, China.

Förderung

  • National Key Laboratory Foundation of China
  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation
  • National Key Research and Development Program of China

Zitieren

APA

Zhang, H., Zhang, L., He, Y., Jiang, D., Sun, J., Luo, Q., Liang, H., Wang, T., Li, F., Tang, Y., Yang, Z., Liu, W., Rao, Y., & Chen, C. (2024). PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer. Cancer Letters, 598, 217112. https://doi.org/10.1016/j.canlet.2024.217112

Vancouver

Zhang H, Zhang L, He Y, Jiang D, Sun J, Luo Q, et al. PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer. Cancer Letters. 2024;598:217112. doi:10.1016/j.canlet.2024.217112

BibTeX
@article{Zhang2024,
  author = {Zhang, Hongyan and Zhang, Longlong and He, Yuna and Jiang, Dewei and Sun, Jian and Luo, Qianmei and Liang, Huichun and Wang, Tiantian and Li, Fubing and Tang, Yu and Yang, Zimo and Liu, Wenjing and Rao, Yu and Chen, Ceshi},
  title = {PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer},
  journal = {Cancer Letters},
  year = {2024},
  volume = {598},
  pages = {217112},
  doi = {10.1016/j.canlet.2024.217112}
}
Kostenlos starten →